Source: European journal of clinical pharmacology. Unidade: FM
Subjects: POLIMORFISMO, FÁRMACOS (SISTEMA NERVOSO PERIFÉRICO), TABAGISMO, CITOCROMO P-450, GENÓTIPOS, FARMACOGENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TOMAZ, Paulo Roberto Xavier et al. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline. European journal of clinical pharmacology, v. 75, n. 11, p. 1541-1545, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00228-019-02731-z. Acesso em: 08 maio 2024.APA
Tomaz, P. R. X., Kajita, M. S., Santos, J. R., Scholz, J., Abe, T. O., Gaya, P. V., et al. (2019). Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline. European journal of clinical pharmacology, 75( 11), 1541-1545. doi:10.1007/s00228-019-02731-zNLM
Tomaz PRX, Kajita MS, Santos JR, Scholz J, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline [Internet]. European journal of clinical pharmacology. 2019 ; 75( 11): 1541-1545.[citado 2024 maio 08 ] Available from: https://doi.org/10.1007/s00228-019-02731-zVancouver
Tomaz PRX, Kajita MS, Santos JR, Scholz J, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PCJL. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline [Internet]. European journal of clinical pharmacology. 2019 ; 75( 11): 1541-1545.[citado 2024 maio 08 ] Available from: https://doi.org/10.1007/s00228-019-02731-z